Trump administration is removing the mainstays of NCI and the federal government’s cancer programPeer review, registries, and evidence-based patient information take a big hit May 09, 2025Vol.51 No.18By Paul Goldberg and Jacquelyn Cobb
Guest Editorial George Weiner: Cancer centers are special, as are site visits in CCSG review May 09, 2025Vol.51 No.18By George J. Weiner
Regulatory News Cyber-iconoclast Vinay Prasad named head of FDA’s CBERAn oncologist, Prasad has criticized accelerated approval, next-gen sequencing, and targeted therapies May 09, 2025Vol.51 No.18By Claire Marie Porter
FreeTrials & Tribulations Working with cancer: Rethinking long-term health for working-age adult cancer survivors May 09, 2025Vol.51 No.18By Susan A. Speckhart, Rebecca Miksad and Lidia Schapira
Sponsored Rewriting the rules of cancer treatment one nanobody at a time May 09, 2025Vol.51 No.18By John D. Fryer
FreeIn the Archives Walter Lawrence Jr.: “The National Cancer Act really gave us a lot of enthusiasm about the future.” May 09, 2025Vol.51 No.18By Katie Goldberg
Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors May 02, 2025Vol.51 No.17By Jacquelyn Cobb
Free Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertileSix years later, she is well—and pregnant with her third child May 02, 2025Vol.51 No.17By Jacquelyn Cobb
White House The White House “skinny budget” document cuts NIH by nearly 40%The cuts are consistent with the previously leaked “passback” document May 02, 2025Vol.51 No.17By Jacquelyn Cobb and Claire Marie Porter
News Analysis NIH eliminates the NCI Board of Scientific AdvisorsOver its 28 year history, BSA shaped NCI-funded extramural science May 02, 2025Vol.51 No.17By Paul Goldberg
